Results 121 to 130 of about 411,697 (349)

Differences in Dynamics of Specific Antinuclear Antibodies and Their Susceptibility to B Cell–Targeting Treatment in Patients With Systemic Lupus Erythematosus

open access: yesArthritis &Rheumatology, EarlyView.
Objective The presence of antinuclear antibodies (ANAs) is characteristic for systemic lupus erythematosus (SLE). Antibody dynamics over time are thought to reflect the cellular source of ANAs and their therapeutic targetability. Anti–double‐stranded DNA (anti‐dsDNA) is the most prevalent and well‐studied of all ANAs, and fluctuations in anti‐dsDNA ...
Hugo J. van Dooren   +16 more
wiley   +1 more source

LP-203 The new markers of systemic lupus erythematosus activity: focus on interleukin (IL)-1b and soluble IL-2 receptor

open access: yesLupus Science and Medicine, 2023
Mariia Aristova   +4 more
doaj   +1 more source

A Case of Tumid Lupus Erythematosus Successfully Treated with Topical Tacrolimus and Hydrocortisone 17-Butyrate

open access: yesGazi Medical Journal
Tumid lupus erythematosus is an uncommon subtype of chronic cutaneous lupus erythematosus. Hereby, we report a 36-year-old male patient with tumid lupus erythematosus who presented with erythematous papules and plaques on the face and neck who showed ...
Funda Tamer   +3 more
doaj   +1 more source

Recurrent podocytopathy in a patient with systemic lupus erythematosus

open access: yesSAGE Open Medical Case Reports, 2017
Podocytopathy in systemic lupus erythematosus is characterised by diffuse foot process effacement without significant peripheral capillary wall immune deposits as seen on electron microscopy.
Shereen Paramalingam   +3 more
doaj   +1 more source

Activin A–Activated ALK4 Induces Pathogenic Th17‐Involved Endothelial–Mesenchymal Transition in Systemic Lupus Erythematosus–Associated Pulmonary Arterial Hypertension

open access: yesArthritis &Rheumatology, EarlyView.
Objective Autoimmune diseases, such as systemic lupus erythematosus (SLE), are associated with pulmonary arterial hypertension (PAH), a condition that can lead to heart failure. However, whether T cells also contribute to the occurrence of PAH in SLE has not been clarified.
Shuliang Jing   +9 more
wiley   +1 more source

LP-048 Characteristics and clinical outcome of incomplete systemic lupus erythematosus

open access: yesLupus Science and Medicine, 2023
Anastasiia Shumilova   +6 more
doaj   +1 more source

Mucosal‐Associated Invariant T Cells in Rheumatic Diseases

open access: yesArthritis &Rheumatology, EarlyView.
Mucosal‐associated invariant T (MAIT) cells are innate‐like T cells defined by their semi‐invariant T cell receptor and restriction by the major histocompatibility complex class I–related molecule (MR1). These cells are primarily activated by microbial‐derived metabolites presented by MR1 or by cytokines.
Manon Lesturgie‐Talarek   +7 more
wiley   +1 more source

LP-027 Overweight and obesity phenotypes based on body mass index and insulin resistance in women with systemic lupus erythematosus

open access: yesLupus Science and Medicine, 2023
Yulia Gorbunova   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy